Rates of Raynaud phenomenon medication initiation are low among patients with SSc in the United States, with less than one-third receiving consistent treatment.

The expanding use of oral PDE5A inhibitors to treat disorders such as pulmonary hypertension ... Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Prevents and Reverses Cardiac Hypertrophy ...